Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 19Terminated 6Active not recruiting 5Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 25NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1

Interventions

Radiotherapy 106Cyclophosphamide 97Cisplatin 75Carboplatin 66Fluorouracil 64Etoposide 61Doxorubicin 60Chemotherapy, Adjuvant 60Vincristine 56Peripheral Blood Stem Cell Transplantation 48Filgrastim 47Paclitaxel 46Gemcitabine 44Cytarabine 41Neoadjuvant Therapy 40Leucovorin 40Docetaxel 35Melphalan 31Oxaliplatin 29Methotrexate 29Ifosfamide 25Gene Expression Profiling 25Amplified Fragment Length Polymorphism Analysis 24Immunohistochemistry 23Dexamethasone 22Irinotecan 21aldesleukin 20Prednisolone 20Interferon-alpha 20Tamoxifen 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × NIH × Dasatinib × Clear all
NCT00112775 2011-06-07

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

National Cancer Institute (NCI)

Phase 2 Unknown
MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡